1093380-08-5

Usage

Uses

Used for preparation of phthalide derivatives for treatment of diabetes.

Upstream product

• 110-85-0 piperazine 
• 865-50-9 iodomethane-d3 
• 142-64-3 piperazine dihydrochloride 

Downstream Products

• 786686-79-1 2-methyl-4-(4-methyl-D3-piperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine 

Relevant academic research and scientific papers

Stable isotope labeled ofloxacin and synthesis method thereof

The invention discloses stable isotope labeled ofloxacin and a synthesis method thereof, wherein stable isotope labeled iodomethane is used as an isotope labeling source and reacted with anhydrous piperazine to obtain stable isotope labeled N-methyl piperazine, and then the stable isotope labeled N-methyl piperazine and fluoroazine carboxylic acid are subjected to a condensation reaction to obtain a stable isotope labeled ofloxacin product. The stable isotope labeling raw materials used in the method are cheap and easy to obtain, the synthesis process is simple, the product is easy to separate and purify, the chemical purity and isotope abundance of the obtained product both reach 99% or above, and the requirement for a standard reagent for quantitative detection of ofloxacin is met; the use value is high, and the economical efficiency is good.

DEUTERIUM-MODIFIED BRIGATINIB DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND USE THEREOF

The present invention relates to the field of pharmaceutical chemistry, and relates to a deuterium-modified Brigatinib derivative, preparation method thereof, pharmaceutical composition containing the same and the uses of the deuterium-modified Brigatinib derivative and the pharmaceutical composition thereof in preparing a medicament for treating the disease mediated by anaplastic lymphoma kinase. The deuterium-modified Brigatinib derivative of the present invention has an excellent inhibitory activity on anaplastic lymphoma kinase and has better pharmacodynamic or pharmacokinetic properties relative to Brigatinib.

KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

THIENOBENZODIAZEPINE MODULATORS OF D1 RECEPTOR, D2 RECEPTOR, AND/OR 5-HT2 RECEPTOR

The present invention relates to new thienobenzodiazepine modulators of D1 receptors, D2 receptors, and/or 5-HT2 receptors, pharmaceutical compositions thereof, and methods of use thereof.